CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today its schedule of key
events at the AABB (formerly known as the American Association of Blood
Banks) Annual Meeting to be held October 7-10 in San Diego, California.
Cerus will be presenting the latest clinical data while blood banks and
hospitals will be publishing results from their own user experience.
Company representatives from Cerus will also be in the exhibition area
at booth 1910.
The AABB Annual Meeting is the largest blood banking conference of the
year globally and scientists and clinicians from around the world will
be attending to hear the latest developments in the industry.
“We are looking forward to AABB and sharing with the blood banking
community the latest clinical data supporting the use of INTERCEPT to
treat blood components,” said Dr. Richard Benjamin, Cerus’ chief medical
officer.
“Between Cerus and our scientific collaborators, we will have 19
abstract presentations including three oral abstracts. The abstracts
this year cover a broad spectrum of topics including platelets, plasma,
red blood cells, whole blood, and emerging pathogens.
In addition, this year at AABB, we will have our first presentation
related to our cryoprecipitate initiative. The abstract shows that
pathogen reduced cryo can be processed from various plasma sources and
can be stored at room temperature for 5 days,” Benjamin continued.
A full list of abstracts can be viewed at https://intercept-usa.com/aabb17.
|
SCHEDULE OF SESSIONS OF INTEREST (listed chronologically):
|
|
|
|
Sunday, October 8
|
|
|
|
2:00 - 3:30 pm - 0224-S TTD II-Pathogen Reduced Platelets:
Implementation Considerations, Convention Center - 20A
|
|
|
|
Monday, October 9
|
|
|
|
2:00 – 2:15 pm – C43-A03F: Compatibility of Apheresis Platelet
Collections with Pathogen Reduction While Maintaining Current Split
Rates, Convention Center – 29A
|
|
5:15 – 5:30 pm – C60-A03J: Robust Inactivation of Mayaro Virus in
Platelet Concentrates and Red Blood Cells Using Nucleic Acid
Targeting Pathogen Reduction Technologies (PRT), Convention Center -
25AB
|
|
|
|
Tuesday, October 10
|
|
|
|
7:00 – 8:15 am – Cerus Presents “Experiences in Implementing
Pathogen Reduction – From Maintaining Split Rates at the Blood
Center to Treating Patients at the Hospital, Convention Center –
29A
|
|
2:30 – 2:45 pm – C92-A04C: Hemovigilance Monitoring of Platelet
Septic Transfusion Reactions (STR) after Treatment with INTERCEPTTM
Pathogen Reduction or Large Volume, Delayed Bact/ALERTTM
Bacterial Culture Screening, Convention Center – 30ABC
|
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171002005354/en/
Source: Cerus Corporation